ATE329598T1 - 1,3-oxathiolane zur behandlung von hepatitis - Google Patents

1,3-oxathiolane zur behandlung von hepatitis

Info

Publication number
ATE329598T1
ATE329598T1 AT92304530T AT92304530T ATE329598T1 AT E329598 T1 ATE329598 T1 AT E329598T1 AT 92304530 T AT92304530 T AT 92304530T AT 92304530 T AT92304530 T AT 92304530T AT E329598 T1 ATE329598 T1 AT E329598T1
Authority
AT
Austria
Prior art keywords
treatment
hepatitis
oxathiolanes
nucleoside analogues
concerned
Prior art date
Application number
AT92304530T
Other languages
English (en)
Inventor
Bernard Belleau
Nghe Nguyen-Ba
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of ATE329598T1 publication Critical patent/ATE329598T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92304530T 1991-05-20 1992-05-19 1,3-oxathiolane zur behandlung von hepatitis ATE329598T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110874A GB9110874D0 (en) 1991-05-20 1991-05-20 Medicaments

Publications (1)

Publication Number Publication Date
ATE329598T1 true ATE329598T1 (de) 2006-07-15

Family

ID=10695296

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92304530T ATE329598T1 (de) 1991-05-20 1992-05-19 1,3-oxathiolane zur behandlung von hepatitis

Country Status (15)

Country Link
US (1) US5486520A (de)
EP (1) EP0515144B1 (de)
JP (3) JP3167788B2 (de)
KR (1) KR100219958B1 (de)
AT (1) ATE329598T1 (de)
CA (1) CA2068943C (de)
DE (1) DE69233631T2 (de)
DK (1) DK0515144T3 (de)
ES (1) ES2270413T3 (de)
GB (1) GB9110874D0 (de)
IE (1) IE921601A1 (de)
IL (1) IL101836A (de)
MX (1) MX9202374A (de)
SG (1) SG47418A1 (de)
ZA (1) ZA923477B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
JP3047045B2 (ja) * 1994-10-22 2000-05-29 チョン クン ダン コーポレーション ヌクレオシド誘導体およびその製造方法
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA005097B1 (ru) 1997-03-19 2004-10-28 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
CA2285577A1 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
CA2340214C (en) 1998-08-12 2007-10-30 Triangle Pharmaceuticals, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
IL142910A0 (en) 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus
IL143867A0 (en) 1998-12-23 2002-04-21 Shire Biochem Inc Antiviral nucleoside analogues
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
US6670342B2 (en) 2000-03-29 2003-12-30 Georgetown University Method of treating hepatitis delta virus infection
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
ATE383355T1 (de) 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
RU2210373C1 (ru) * 2002-07-03 2003-08-20 Государственное учреждение Тверская государственная медицинская академия Способ лечения тяжелого и затяжного течения острого вирусного гепатита
KR20110031250A (ko) * 2002-07-15 2011-03-24 길리애드 사이언시즈, 인코포레이티드 B형 간염 바이러스 감염의 치료를 위한 l-fmau를 사용한 병용 치료
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
RU2240116C1 (ru) * 2003-08-20 2004-11-20 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Дезинтоксикационный инфузионный раствор
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
FR3136975A1 (fr) 2022-06-22 2023-12-29 L'oreal Composition d’éclaircissement des fibres kératiniques et procédé d’éclaircissement des fibres kératiniques mettant en œuvre cette composition
FR3170286A1 (fr) 2024-12-23 2026-06-26 L'oreal Procede de traitement des fibres keratiniques comprenant les applications d’une premiere composition oxydante et d’une seconde composition a base de colorants directs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
JPH04501854A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
EP0472663A4 (en) * 1989-05-15 1992-07-01 Us Commerce Method of treatment of hepatitis
ATE183508T1 (de) * 1989-06-27 1999-09-15 Wellcome Found Therapeutische nukleoside
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
JP2960164B2 (ja) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド 抗ウイルス特性を有する置換1,3−オキサチオラン類および置換1,3−ジチオラン類
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
IL101836A (en) 1997-03-18
IL101836A0 (en) 1992-12-30
KR100219958B1 (ko) 1999-09-01
DE69233631T2 (de) 2007-05-24
JP2001226268A (ja) 2001-08-21
SG47418A1 (en) 1998-04-17
GB9110874D0 (en) 1991-07-10
US5486520A (en) 1996-01-23
MX9202374A (es) 1994-06-30
EP0515144B1 (de) 2006-06-14
DE69233631D1 (de) 2006-07-27
CA2068943C (en) 2000-11-28
JP3167788B2 (ja) 2001-05-21
ZA923477B (en) 1993-01-27
ES2270413T3 (es) 2007-04-01
DK0515144T3 (da) 2006-10-09
CA2068943A1 (en) 1992-11-21
IE921601A1 (en) 1992-12-02
KR930019213A (ko) 1993-10-18
AU1635192A (en) 1992-11-26
AU656961B2 (en) 1995-02-23
EP0515144A1 (de) 1992-11-25
JPH11322608A (ja) 1999-11-24
HK1005542A1 (en) 1999-01-15
JPH05202045A (ja) 1993-08-10

Similar Documents

Publication Publication Date Title
DE69233631D1 (de) 1,3-Oxathiolane zur Behandlung von Hepatitis
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
MA22144A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane .
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE138065T1 (de) Substituierte 1,3-oxathiolane mit antiviraler wirkung
DK0634927T3 (da) Behandling og profylakse af sygdomme forårsaget af parasitter eller bakterier
DE3855099D1 (de) Nucleoside zur Verwendung für die Therapie
ATE469147T1 (de) Antivirale wirkung und auflösung von 2- hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3- oxathiolanen
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
CY1110629T1 (el) Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
ATE157877T1 (de) Verbindung von nucleocidanaloga zur behandlung viraler infektionen
DK557087A (da) Forbindelse til behandling af retrovirusinfektioner
ATE107506T1 (de) Antiretroviraler castanosperminester.
ES2043609T3 (es) Composiciones de interleucina-2.
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
ES2182847T3 (es) Nucleosidos y nucleotidos de anillo expandido.
ATE96317T1 (de) Verwendung von 5-(subst. phenyl)oxazolidinonderivaten zur behandlung von depressionen.
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
DE3687895D1 (de) Arginin- und agmatinderivate zur behandlung von protozoen-infektionen.
ATE96029T1 (de) Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5- ethyluracil.
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.
UY24534A1 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0515144

Country of ref document: EP

EEFA Change of the company name